e-Edition
Obituaries
Special Sections
Special Occasions
Contact
Subscribe
Paywall Login
Login to Comment
Register
December 11th, 2017
jobs
homes
Menu
Home
News
Sports
Business
Entertainment
Classifieds
Commentary
Recent Quotes
View Full List
My Watchlist
Artelo Biosciences, Inc. - Common Stock
Blue Earth Resources Inc
Cematrix Corp
Cresco Labs Inc
Dye and Durham Limited
ExlService Holdings, Inc. - Common Stock
Fidelity Disruptors ETF
Finch Therapeutics Group, Inc. - Common Stock
FirstCash Holdings, Inc. - Common Stock
Foremost Clean Energy Ltd. - Warrant
L.B. Foster Company - Common Stock
Mercedes Benz Group Ag
Mitsubishi Motors
Mondee Holdings, Inc. - Class A Common Stock
Pegasystems Inc. - Common Stock
Perpetua Resources Corp
Salem Media Group, Inc. - Class A Common Stock
Schwab Municipal Bond ETF
Shift Technologies, Inc. - Class A Common Stock
Silo Pharma, Inc. - Common Stock
Simulations Plus, Inc. - Common Stock
Spectra7 Microsystems Inc
Sprott Gold Miners ETF
Strategic Metals Ltd New
Strive, Inc. - Class A Common Stock
Stryve Foods, Inc. - Class A Common Stock
Swiss Water Decaffeinated Coffee Inc
Thomson Reuters Corporation
Uniper Se
WisdomTree Space Economy Fund
authID Inc. - Common Stock
iShares Russell 1000 Value ETF
Edit Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Vogenx Inc - Common Stock
(NQ:
VOGX
)
14.53
-1.52 (-9.47%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 16, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Vogenx Inc - Common Stock
Vogenx Initiates Phase 2b EMERGE Study of Mizagliflozin for Post-Bariatric Hypoglycemia
October 15, 2026
Randomized, double-blind, placebo-controlled trial will evaluate two doses of the first-in-class, minimally absorbed SGLT1 inhibitor in patients with recurrent hypoglycemia following bariatric surgery
From
Vogenx, Inc.
Via
ACCESS Newswire
Vogenx Appoints Board Member Richard Gorman as Chief Commercial Officer
October 09, 2026
Thirty-year biopharmaceutical commercial leader transitions from the Board of Directors to Chief Commercial Officer Appointment strengthens corporate strategy, business development and commercial...
From
Vogenx, Inc.
Via
ACCESS Newswire
Vogenx Appoints Ken Toombs to Board of Directors
September 22, 2026
Former Chief Executive Officer of PA Consulting brings three decades of global professional services and life sciences leadership experience Appointment broadens independent oversight as the Company...
From
Vogenx, Inc.
Via
ACCESS Newswire
Vogenx Announces Closing of Initial Public Offering
August 13, 2026
From
Vogenx, Inc.
Via
ACCESS Newswire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.